<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Key to the clinical management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is identifying tools which aid in assessing patient prognosis and determining more effective and personalised treatment strategies </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated whether an experimental systems biology strategy which analyses the susceptibility of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to undergo caspase activation can be exploited to predict patient responses to <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>-based chemotherapy and to case-specifically identify potential alternative targeted treatments to reactivate <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: We quantified five essential <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-regulating proteins (Pro-Caspases 3 and 9, APAF-1, SMAC and XIAP) in samples of Stage II (n = 13) and III (n=17) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> colonic (n = 8) tissue using absolute quantitative immunoblotting and employed systems simulations of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> signalling to predict the susceptibility of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells to execute <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Additional systems analyses assessed the efficacy of novel <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing therapeutics such as XIAP <z:chebi fb="68" ids="48706">antagonists</z:chebi>, <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> and Pro-Caspase-3-activating compounds in restoring <z:mpath ids='MPATH_3'>apoptosis</z:mpath> execution in <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-incompetent <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Comparisons of caspase activity profiles demonstrated that the likelihood of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumours</z:e> to undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath> decreases with advancing disease stage </plain></SENT>
<SENT sid="5" pm="."><plain>Systems-level analysis correctly predicted positive or negative outcome in 85% (p=0.004) of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients receiving <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> based chemotherapy and significantly outperformed common uni- and multi-variate statistical approaches </plain></SENT>
<SENT sid="6" pm="."><plain>Modelling of individual patient responses to novel <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing therapeutics revealed markedly different inter-individual responses </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our study represents the first proof-of-concept example demonstrating the significant clinical potential of systems biology-based approaches for predicting patient outcome and responsiveness to novel targeted treatment paradigms </plain></SENT>
</text></document>